BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 96 filers reported holding BIOXCEL THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.86 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $27,142 | -72.0% | 21,205 | -38.3% | 0.00% | -100.0% |
| Q1 2024 | $96,966 | -7.1% | 34,385 | -2.8% | 0.00% | 0.0% |
| Q4 2023 | $104,386 | -32.9% | 35,385 | -42.5% | 0.00% | 0.0% |
| Q3 2023 | $155,608 | -60.9% | 61,505 | +3.0% | 0.00% | -66.7% |
| Q2 2023 | $397,635 | -73.5% | 59,705 | -25.6% | 0.00% | -75.0% |
| Q1 2023 | $1,498,305 | -55.6% | 80,295 | -48.9% | 0.01% | -57.1% |
| Q4 2022 | $3,375,000 | +163.1% | 157,105 | +44.7% | 0.03% | +154.5% |
| Q3 2022 | $1,283,000 | +13.4% | 108,545 | +26.7% | 0.01% | +22.2% |
| Q2 2022 | $1,131,000 | +60.7% | 85,670 | +154.3% | 0.01% | +80.0% |
| Q1 2022 | $704,000 | -0.1% | 33,682 | -2.9% | 0.01% | 0.0% |
| Q4 2021 | $705,000 | +2.9% | 34,682 | +53.7% | 0.01% | 0.0% |
| Q3 2021 | $685,000 | +69.1% | 22,570 | +62.1% | 0.01% | +66.7% |
| Q2 2021 | $405,000 | -61.1% | 13,925 | -42.3% | 0.00% | -70.0% |
| Q1 2021 | $1,042,000 | +217.7% | 24,150 | +240.1% | 0.01% | +233.3% |
| Q4 2020 | $328,000 | – | 7,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 315,000 | $7,040,000 | 3.41% |
| Ikarian Capital, LLC | 693,716 | $15,505,000 | 1.17% |
| EAM Global Investors LLC | 71,838 | $1,606,000 | 0.94% |
| Avidity Partners Management LP | 211,000 | $4,716,000 | 0.65% |
| MOODY ALDRICH PARTNERS LLC | 79,642 | $1,780,000 | 0.54% |
| Knoll Capital Management, LLC | 20,000 | $447,000 | 0.42% |
| EAM Investors, LLC | 55,775 | $1,247,000 | 0.39% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 299,932 | $6,703,000 | 0.22% |
| Coastal Bridge Advisors, LLC | 25,014 | $559,000 | 0.20% |
| Ikarian Capital, LLC | 103,300 | $2,309,000 | 0.17% |